the standard-dose group (4 g/day)
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Dec 21, 2023 → Jan 30, 2026
NCT ID
NCT06186934About the standard-dose group (4 g/day)
the standard-dose group (4 g/day) is a pre-clinical stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06186934. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 15 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (13)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06186934 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Hyperphosphatemia